Moderna Inc (MRNA_KZ)

71.00 0.00 (0.00%)
Delayed Data USD Disclaimer

Moderna Inc Company Profile

Equity Type
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Contact Information
Cambridge,02139 United States
617 714 6500
Top Executives
Robert S. Langer 73 2010 Independent Non Executive Director & Member of Scientific Advisory Board
Elizabeth G. Nabel 70 2021 Independent Director
Ulrich H. von Andrian-Werburg 0 0000 Member of Scientific Advisory Board
John G. Aunins 61 2014 Member of Technology Advisory Board
Scott A. Canute 61 2014 Member of Technology Advisory Board
Fred E. Regnier 0 2014 Member of Technology Advisory Board
James R. Swartz 0 2014 Member of Technology Advisory Board
Richard C. Willson 0 2014 Member of Technology Advisory Board
Elizabeth Edith Tallett 72 2020 Independent Director
Sandra J. Horning 73 2020 Independent Director
Jack W. Szostak 0 2014 Chairman of Scientific Advisory Board
Noubar B. Afeyan 60 2010 Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board
Stephane Bancel 50 2011 CEO & Director
Ron Eydelloth 0 0000 Member of Scientific Advisory Board
Rachel Green 0 0000 Member of Scientific Advisory Board
Paul L. Sagan 64 2018 Independent Non Executive Director
Ralph Weissleder 0 0000 Member of Scientific Advisory Board
Paula T. Hammond 59 0000 Member of Scientific Advisory Board
Michael Diamond 0 0000 Member of Scientific Advisory Board
Stephen A. Berenson 62 2017 Independent Non Executive Director
Francois Nader 66 2019 Independent Non Executive Director
Melissa J. Moore 0 2016 Chief Scientific Officer & Member of Scientific Advisory Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles